Program of the 10th AMR Conference | March 3 - 4, 2026
March 3, 2026 Congress Center 2nd floor
08:45 – 10:30 | General Assembly | Room Osaka/Samarkand
Open only to members of the BEAM Alliance
11:00 – 12:00 | Plenary session | Room Sydney
Moderator: Florence Séjourné, AUROBAC Therapeutics & BEAM Alliance
Speakers:
Kevin Outterson, CARB-X
John Rex, AMR.Solutions
Evan Loh, Paratek Pharma
Hala Audi, Quantoom Biosciences
12:00 – 13:30 | Lunch break
13:30 – 14:30 | Plenary session | Room Sydney
Moderator: will be announced soon
Speakers:
Alex Tweddle, Angry Man Pictures
Laura Alonso Irujo, Spanish Agency for Medicines and Health Products (AEMPS)
Further speakers to be announced
15:00 – 16:00 | Parallel sessions
Room Sydney
Moderator: Peter Seiler, INCATE
Speakers:
Valeria Gigante, World Health Organization
Julia Djonova, Swissmedic
Neha Prasad, Rubrum Advising
Eric van der Helm, SNIPR Biome
Room Singapore
Moderator: Yann Ferrisse, GARDP
Speakers:
Bennoit Hennion, Tamrisa
Leela Maitreyi, Bugworks
Morgane Vanbiervliet, Debiopharm
Innovation is what innovators do. But in AMR, scientific innovation alone is not enough. When markets are weak or missing, survival may depend on building truly innovative business models.
Join the session “Antimicrobial business models” moderated by Yann Ferrisse, GARDP, and highlighting inspiring ways to rethink how we finance development and create viable pathways to market.
🔹 Morgane Vanbiervliet will walk us through Debiopharm’s model, running AMR and oncology development in parallel
🔹 Benoit Hennion will share how Tamrisa combines the sales of established antimicrobials with the development of new ones
🔹 Leela Maitreyi will present Bugworks’ approach: focusing access and commercialization where the bugs actually are
And you — how are you thinking about your business model?
Come and discuss it with the experts.
Room Osaka/Samarkand
Moderator: will be announced soon
Speakers:
York Zöllner, Hamburg University of Applied Sciences
Further speakers to be announced
16:00 – 16:30 | Poster presentations
16:30 – 17:30 | Parallel sessions
Room Sydney
Moderator: Christoph Dehio, NCCR AntResist
Speakers:
Jan Rybniker, University Hospital Cologne
Lauriane Cabon, F. Hoffmann-La Roche
Cesar de la Fuente, University of Pennsylvania
If you’re driven by innovation and scientific breakthroughs, this is a session you won’t want to miss. Join us for an inspiring discussion where leading scientists will share cutting-edge approaches that are reshaping the field.
Moderated by Christoph Dehio and NCCR AntiResist, this session brings together outstanding experts:
🔹 Jan Rybniker will explore the promise of antibacterial antibodies
🔹 Lauriane Cabon will highlight how organoid technologies can transform research and development
🔹 Cesar de la Fuente will showcase the immense potential of deep learning to accelerate antibiotic discovery
Expect thought-provoking insights, lively discussion, and the chance to connect with a community of forward-thinking researchers and innovators.
presented by
Room Singapore
Moderator: Carmen Coxon, Medicines and Healthcare products Regulatory Agency UK
Speakers:
Frédérique Vieville, 5QBD
Helerin Eiche, Estonia State Agency of Medicines
Frédéric Laurent, Hospices Civils de Lyon
Phage therapy has a century-long history, but integrating it into modern medicine raises unique regulatory and industrial challenges. Moderated by MHRA expert Carmen Coxon, this session explores how this long-standing biological approach is being reframed for contemporary clinical use—balancing efficacy, safety, and regulatory oversight.
You’ll hear from leading European experts addressing both recent regulatory advances and the critical gaps that still need to be bridged for phage therapies to scale:
🔹 Helerin Eiche, Estonian Health Agency: An overview of the newly released EMA guideline on bacteriophage medicinal products
🔹 Frédérique Vieville, 5QBD Biotech: From guidelines to practice: key regulatory signals emerging from European expert and industrial discussions on phage therapy
🔹 Frédéric Laurent, Hospices Civil de Lyon: The pivotal role of Phage Susceptibility Testing in the regulated use of phage products—and what still limits its implementation today
By the end of this session, participants will gain a global picture of the current European regulatory landscape for phage therapy, highlighting what is now better framed, what remains under discussion, and how regulatory thinking is progressively evolving.
Room Osaka/Samarkand
Moderator: Rachel Freeman, IQVIA
Speakers:
Bob de Vos, Nostics
Marco Caproni, TÜV SÜD
Further speakers to be announced
presented by
18:00 – 19:30 | Pitch session | Room Sydney
Moderator: Guillermo Tramontin, Cavenagh Health
Running order of pitching companies:
will be published in February 2026
Organized by
Prize kindly sponsored by
19:30 – 21:00 | Evening reception
March 4, 2026 Congress Center 2nd floor
08:30 – 09:30 | Plenary session | Room Sydney
Moderator: Richard Alm, CARB-X
Speakers:
David Paterson, National University of Singapore
Drew Lewis, Innoviva Specialty Therapeutics
Claude Mabilat, bioMérieux
10:00 – 11:00 | Parallel sessions
Room Sydney
Moderator: will be announced soon
Speakers:
Radu Botgros, European Medicines Agency
Mihai Rotaru, EFPIA
Further speakers to be announced
Room Singapore
Moderator: Suzanne Edwards, Global AMR R&D Hub
Speakers:
Cesar Hernandez, Spanish Ministry of Health
Ana Burgos Gutierrez, European Commission
Further speakers to be announced
Room Osaka/Samarkand
Moderator: Lucas Boeck, University of Basel
Speakers:
Hee-Jong Hwang, A&J Science
Nicola Ivan Lorè, Ospedale San Raffaele
Alexandra Aubry, Sorbonne University
11:00 – 11:30 | Poster presentations
11:30 – 12:30 | Plenary session | Room Sydney
Moderator: Damien Somé, GARDP
Speakers:
Jinyan Liu, Tigermed
Yonghong Xiao, Zhejiang University
Further speakers to be announced
12:30 – 12:45 | Plenary session | Room Sydney
Moderator: will be announced soon
Organized by
Prizes kindly sponsored by
12:45 – 14:00 | Lunch break
14:00 – 15:00 | Parallel sessions
Room Sydney
Moderator: Lisa Husband, BioVersys
Speakers:
Paul McGovern, Venatorx Pharmaceuticals
Rienk Pypstra, tranScrip
Evan Loh, Paratek Pharma
Room Singapore
Moderator: Betsy Wonderly-Trainor, CARB-X
Speakers:
Martin Everett, AUROBAC Therapeutics
Michael Lobritz, F. Hoffmann-La Roche
Michael Hombach, F. Hoffmann-La Roche
Romney Humphries, Vanderbilt University Medical Center
Room Osaka/Samarkand
Moderator: Delphine Croisier, Vivexia
Speakers:
Kristof van Emelen, Obulytix
Subhendu Basu, Telum Therapeutics
Yeung-Hyen Kim, iNtRON Biotechnology
Mark Beards, Santero Therapeutics
15:30 – 16:30 | Parallel sessions
Room Sydney
Moderator: Robert Kimbui, GARDP
Speakers:
Christopher Lim, PAHO Strategic Fund
Adnaan Ghanchi, ARMoR
Priya Balasubramaniam, Public Health Foundation India
Further speakers to be announced
Room Singapore
Moderator: Jennifer Schneider, Centauri Therapeutics
Speakers:
Sharon Hughes, IQVIA
Marc Lemonnier, Antabio
Chad Testa, Curza
Room Osaka/Samarkand
Moderator: Mateusz Hasso-Agopsowicz, World Health Organization
Speakers:
Juanjo Infante, Vaxdyn
Marta Vieira, ImmuneThep
Patricia Martin, LimmaTech Biologics
Is there a problem with vaccine development in AMR?
The pipeline remains worryingly thin, which means every failure has a major impact on our future ability to prevent resistant infections. Unfortunately, we’ve seen several high-profile setbacks recently.
In the session “Next-Gen Vaccines: Building Smart Strategies,” moderated by Mateusz Hasso-Agopsowicz (WHO), we’ll explore concrete approaches to de-risking the development of these critical assets:
🔹 Patricia Martin (LimmaTech) will highlight challenges in clinical development using an example of a vaccine development against S. Aureus.
🔹 Marta Vieira (Immunethep) will present how AI-driven design can help reduce the size of control groups in clinical studies.
🔹 Juanjo Infante will share key lessons learned from an observational study conducted by Vaxdyn.
17:00 – 18:00 | Plenary session | Room Sydney
Moderator: Marc Gitzinger, BioVersys & BEAM Alliance
Speakers:
Dame Sally Davies, UK Special Envoy on AMR
Nina Khanna, University Hospital Basel
Henry Skinner, AMR Action Fund
Further speakers to be announced
18:00 – 19:00 | Farewell reception
BEAM Alliance program committee
Marc Gitzinger
Florence Séjourné
